Vascular Disruptive Agents for the Treatment of Cancer
Tumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. Two approaches have been explored for cancer t...
Συγγραφή απο Οργανισμό/Αρχή: | |
---|---|
Άλλοι συγγραφείς: | |
Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
Γλώσσα: | English |
Έκδοση: |
New York, NY :
Springer New York : Imprint: Springer,
2010.
|
Θέματα: | |
Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Development of Vascular Disrupting Agents
- Development of Vascular Disrupting Agents
- Pre-Clinical Development
- The Discovery and Characterisation of Tumour Endothelial Markers
- The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs)
- Combination Therapy with Chemotherapy and VDAs
- Lessons from Animal Imaging in Preclinical Models
- Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action
- Imaging in the Development of Vascular Disruptive Agents
- MRI to Assess Vascular Disruptive Agents
- Contrast Ultrasound in Imaging Tumor Angiogenesis
- Clinical Development
- The Clinical Development of Tubulin Binding Vascular Disrupting Agents
- ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy
- Vascular Disruptive Agents in Combination with Radiotherapy.